Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-blockstyrene) surgical device for the treatment of primary open-angle glaucoma: a review
作者机构：Santen IncEmeryvilleCAUSA. InnFocus Inc.a Santen CompanyMiamiFLUSA Bascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineMiamiFLUSA
出 版 物：《Eye and Vision》 (眼视光学杂志（英文）)
年 卷 期：2019年第6卷第1期
页 面：303-311页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：support was provided by Lucy Cartwright,MChem,Helios Medical Communications,Cheshire,UK funded by Santen.MicroShunt studies were sponsored by InnFocus,a Santen company
主 题：Ab externo Glaucoma Micro-invasive glaucoma surgery MicroShunt Mitomycin C SIBS polymer
摘 要：Trabeculectomy remains the‘gold standard’intraocular pressure(IOP)-lowering procedure for moderate-to-severe glaucoma;however,this approach is associated with the need for substantial post-operative *** glaucoma surgery(MIGS)procedures aim to reduce the need for intra-and post-operative management and provide a less invasive means of lowering ***,MIGS procedures are associated with only modest reductions in IOP and are targeted at patients with mild-to-moderate glaucoma,highlighting an unmet need for a less invasive treatment of advanced and refractory *** PRESERFLO®MicroShunt(formerly known as InnFocus MicroShunt)is an 8.5 mm-long(outer diameter 350μm;internal lumen diameter 70μm)glaucoma drainage device made from a highly biocompatible,bioinert material called poly(styrene-block-isobutylene-blockstyrene),or *** lumen size is sufficiently small that at normal aqueous flow hypotony is avoided,but large enough to avoid being blocked by sloughed cells or *** MicroShunt achieves the desired pressure range in the eye by draining aqueous humor from the anterior chamber to a bleb formed under the conjunctiva and Tenon’s *** device is implanted ab externo with intraoperative Mitomycin C via a minimally invasive(relative to incisional surgery)surgical procedure,enabling precise control of placement without the need for gonioscopy,suture tension control,or suture *** implantation procedure can be performed in combination with cataract surgery or as a standalone *** MicroShunt received ConformitéEuropéenne(CE)marking in 2012 and is intended for the reduction of IOP in eyes of patients with primary open-angle glaucoma in which IOP remains uncontrolled while on maximum tolerated medical therapy and/or in which glaucoma progression warrants *** clinical studies assessing the long-term safety and efficacy of the MicroShunt have been completed;a Phase 3 multicenter,randomized clinical study comp
维普期刊数据库